The present study was undertaken to evaluate GZ17-6.02, a novel anti-cancer agent which is currently undergoing phase I trials in various cancers [14,15,16,17], for its growth inhibition of glioblastomas expressing a specific form of EGFR, namely EGFRvIII. This evidence concerns the gene EGFR and glioblastoma.